Moreover, the Conzen group at UT Southwestern has shown evidence that some triple negative breast cancers (TNBCs), which are not LKB1 mutant, activate a glucocorticoid mediated, GR driven transcriptional response that is antagonistic to chemotherapy thus potentially leading to poor outcomes (34). This evidence concerns the gene STK11 and triple-negative breast carcinoma.